Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature

被引:301
作者
Cai, Weibo [1 ,2 ]
Chen, Kai [1 ,2 ]
Li, Zi-Bo [1 ,2 ]
Gambhir, Sanjiv S. [1 ,2 ,3 ]
Chen, Xiaoyuan [1 ,2 ]
机构
[1] Stanford Univ, Sch Med, Dept Radiol, Mol Imaging Program Stanford MIPS, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Bio X Program, Stanford, CA 94305 USA
[3] Stanford Univ, Sch Med, Dept Bioengn, Stanford, CA 94305 USA
关键词
dual-function probe; PET; near-infrared fluorescence; quantum dot; integrin alpha(v)beta(3);
D O I
10.2967/jnumed.107.043216
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
To date, the in vivo imaging of quantum dots (QDs) has been mostly qualitative or semiquantitative. The development of a dual-function PET/near-infrared fluorescence (NIRF) probe can allow for accurate assessment of the pharmacokinetics and tumor-targeting efficacy of QDs. Methods: A QD with an amine-functionalized surface was modified with RGD peptides and 1,4,7,10-tetraazacyclodocecane-N,N',N '',N'"-tetraacetic acid (DOTA) chelators for integrin alpha(v)beta(3)-targeted PET/NIRF imaging. A cell-binding assay and fluorescence cell staining were performed with U87MG human glioblastoma cells (integrin alpha(v)beta(3)-positive). PET/NIRF imaging, tissue homogenate fluorescence measurement, and immunofluorescence staining were performed with U87MG tumor-bearing mice to quantify the probe uptake in the tumor and major organs. Results: There are about 90 RGD peptides per QD particle, and DOTA-QD-RGD exhibited integrin (alpha(v)beta(3)-Specific binding in cell cultures. The U87MG tumor uptake of Cu-64-labeled DOTA-QD was less than 1 percentage injected dose per gram (%ID/g), significantly lower than that of Cu-64-labeled DOTA-QD-RGD (2.2 +/- 0.3 [mean +/- SD] and 4.0 +/- 1.0 %ID/g at 5 and 18 h after injection, respectively; n = 3). Taking into account all measurements, the liver-, spleen-, and kidney-to-muscle ratios for 64Cu-labeled DOTA-QD-RGD were about 100: 1, 40:1, and 1:1, respectively. On the basis of the PET results, the U87MG tumor-to-muscle ratios for DOTA-QD-RGD and DOTA-QD were about 4:1 and 1: 1, respectively. Excellent linear correlation was obtained between the results measured by in vivo PET imaging and those measured by ex vivo NIRF imaging and tissue homogenate fluorescence (r(2) = 0.93). Histologic examination revealed that DOTA-QD-RGD targets primarily the tumor vasculature through an RGD-integrin alpha(v)beta(3) interaction, with little extravasation. Conclusion: We quantitatively evaluated the tumor-targeting efficacy of a dual-function OD-based probe with PET and NIRF imaging. This dual-function probe has significantly reduced potential toxicity and overcomes the tissue penetration limitation of optical imaging, allowing for quantitative targeted imaging in deep tissue.
引用
收藏
页码:1862 / 1870
页数:9
相关论文
共 39 条
[1]   Nanocrystal targeting in vivo [J].
Åkerman, ME ;
Chan, WCW ;
Laakkonen, P ;
Bhatia, SN ;
Ruoslahti, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (20) :12617-12621
[2]   Noninvasive imaging of quantum dots in mice [J].
Ballou, B ;
Lagerholm, BC ;
Ernst, LA ;
Bruchez, MP ;
Waggoner, AS .
BIOCONJUGATE CHEMISTRY, 2004, 15 (01) :79-86
[3]   Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects [J].
Cai, WB ;
Shin, DW ;
Chen, K ;
Gheysens, O ;
Cao, QZ ;
Wang, SX ;
Gambhir, SS ;
Chen, XY .
NANO LETTERS, 2006, 6 (04) :669-676
[4]   Are quantum dots ready for in vivo imaging in human subjects? [J].
Cai, Weibo ;
Hsu, Andrew R. ;
Li, Zi-Bo ;
Chen, Xiaoyuan .
NANOSCALE RESEARCH LETTERS, 2007, 2 (06) :265-281
[5]  
Cai WB, 2007, J NUCL MED, V48, P304
[6]   Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression [J].
Cai, Weibo ;
Chen, Xiaoyuan .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 :4267-4279
[7]   How molecular imaging is speeding up antiangiogenic drug development [J].
Cai, Weibo ;
Rao, Jianghong ;
Gambhir, Sanjiv S. ;
Chen, Xiaoyuan .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (11) :2624-2633
[8]   In vitro and in vivo characterization of 64Cu-labeled Abegrin™ a humanized monoclonal antibody against integrin αvβ3 [J].
Cai, Weibo ;
Wu, Yun ;
Chen, Kai ;
Cao, Qizhen ;
Tice, David A. ;
Chen, Xiaoyuan .
CANCER RESEARCH, 2006, 66 (19) :9673-9681
[9]  
Cai WB, 2006, J NUCL MED, V47, P2048
[10]  
Cai Weibo, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P407, DOI 10.2174/187152006778226530